Current Time 0:00
/
Duration Time 0:00
Progress: NaN%
Playback Rate
1.00x

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation

Research Square

Research Square

  • First Author :
    Alok A. Khorana
  • Co-authors :
    Keith McCrae, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B. Streiff
  • Journal Name :
    Hematology
  • Read Full text :
  • DOI :
    10.1002/ajh.25361

Share This Video

Abstract

Recently, a real‐world study of primarily Medicare‐insured patients compared the risk of recurrent venous thromboembolism (VTE) and major bleeding associated with rivaroxaban, warfarin, and low‐molecular weight heparin (LMWH) following a first‐episode of VTE among patients with cancer.1 Results suggested that rivaroxaban treatment is associated with a lower risk of recurrent VTE versus LMWH or warfarin, and that the rate of major bleeding does not significantly differ across treatments.1 As this original study was conducted among an elderly population (age ≥65 years), we sought to assess the risk of recurrent VTE and major bleeding associated with rivaroxaban, LMWH, and warfarin treatment following a first‐episode of VTE in commercially‐insured—and younger—patients.

Ask Questions 0

Please Login or Register to add your question

Recommended Videos

No recommendation found